Results 11 to 20 of about 33,240 (248)
Viruses, 2020 Peptides derived from the C-terminal heptad repeat (CHR) region of HIV-1 gp41 is potent viral membrane fusion inhibitors, such as the first clinically approved peptide drug T20 and a group of newly-designed peptides.
Danwei Yu +7 more
doaj +1 more source
Clinical perspective of fusion inhibitors for treatment of HIV [PDF]
Journal of Antimicrobial Chemotherapy, 2004 The number of antiretroviral-experienced HIV patients with multiple resistances against the currently available antiretroviral drug classes is increasing substantially. Therapeutic options for this specific group of patients are limited. The fusion inhibitor enfuvirtide represents the first new therapeutic option from a new drug class for this patient ...
J K, Rockstroh, S, Mauss
openaire +2 more sources
Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
Viruses, 2013 The hydrophobic pocket in the HIV-1 gp41 N-terminal heptad repeat (NHR) domain plays an important role in viral fusion and entry into the host cell, and serves as an attractive target for development of HIV-1 fusion/entry inhibitors. The peptide anti-HIV
Asim K. Debnath +5 more
doaj +1 more source
Resistance to enfuvirtide, the first HIV fusion inhibitor [PDF]
Journal of Antimicrobial Chemotherapy, 2004 Fusion inhibitors are a new class of antiretroviral drugs (ARVs) for the treatment of human immunodeficiency virus infection. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral ...
Michael L, Greenberg, Nick, Cammack
openaire +2 more sources
Biochemistry and Biophysics Reports, 2019 Cell-to-cell spread of HIV permits ongoing viral replication in the presence of antiretroviral therapy and is suggested to be a major contributor to sexual transmission by mucosal routes.
Mohammad Mamun Alam +10 more
doaj +1 more source
HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins
Molecular Therapy: Nucleic Acids, 2018 HIV entry is a highly specific and time-sensitive process that can be divided into receptor binding, coreceptor binding, and membrane fusion. Bifunctional antiviral proteins (bAVPs) exploit the multi-step nature of the HIV entry process by binding to two
Alexander Falkenhagen, Sadhna Joshi
doaj +1 more source
Emerging Microbes and Infections, 2022 Emerging studies indicate that infusion of HIV-resistant cells could be an effective strategy to achieve a sterilizing or functional cure. We recently reported that glycosylphosphatidylinositol (GPI)-anchored nanobody or a fusion inhibitory peptide can ...
Yue Chen +7 more
doaj +1 more source
A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. [PDF]
PLoS ONE, 2013 Fusion inhibitors are a class of antiretroviral drugs used to prevent entry of HIV into host cells. Many of the fusion inhibitors being developed, including the drug enfuvirtide, are peptides designed to competitively inhibit the viral fusion protein ...
Matthew P Wood +8 more
doaj +1 more source
Retrovirology, 2012 Background Most currently approved anti-HIV drugs (e.g., reverse transcriptase inhibitors, protease inhibitors and fusion/entry inhibitors) must act inside or on surface of the target cell to inhibit HIV infection, but none can directly inactivate ...
Lu Lu +5 more
doaj +1 more source
An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors. [PDF]
PLoS ONE, 2011 HIV-1 envelope glycoproteins (Envs) mediate virus entry by fusing the viral and target cell membranes, a multi-step process that represents an attractive target for inhibition.
Alon Herschhorn +6 more
doaj +1 more source